A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Inclusion Criteria:

• Diagnosis of ulcerative colitis (UC) established at least 3 months

• Moderately to severely active UC assessed by mMS

• Inadequate response, loss of response, or intolerance to conventional or advancedtherapies for UC

Exclusion Criteria:

• Prior extensive colonic resection, subtotal or total colectomy, or planned surgeryfor UC

• Diagnosis of Crohn's disease or indeterminate colitis

• Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)

• Inadequate response, loss of response, or intolerance to treatment of UC with anadvanced therapy targeted at IL-12 and/or IL-23